Group 1 - The core point of the article is that BeiGene (06160.HK) announced the grant of restricted stock units to 188 recipients, totaling 21,197 American Depositary Shares, equivalent to 275,561 shares, which represents approximately 0.02% of the company's total issued shares as of the announcement date [1] Group 2 - The grant was made by the company's board compensation committee in accordance with the terms of the 2016 option and incentive plan [1]

Core Viewpoint - Chow Tai Fook Jewelry Group Limited (00659.HK) announced the conversion of its HKD 850 million 2.80% convertible bonds due in 2027 into new shares, with all outstanding bonds expected to be converted by March 10, 2026 [1] Group 1 - The company has delivered conversion notices for all outstanding bonds to the main agent as of the announcement date [1] - Following the conversion, there will be no outstanding bonds issued by the company [1] - The board has notified the Vienna Stock Exchange that the last trading day for the bonds will be March 6, 2026, and the bonds are expected to be delisted on March 10, 2026 [1]

Group 1 - The company, Kowloon Development (00034.HK), announced that it will hold a board meeting on March 20, 2026, to consider and approve the annual performance for the year ending December 31, 2025, for itself and its subsidiaries [1] - The board meeting will also consider the payment of the final dividend [1]

Core Viewpoint - Kerry Properties (00683.HK) will hold a board meeting on March 23, 2026, to approve the annual performance announcement for the fiscal year ending December 31, 2025, and to consider the distribution of a final dividend, if any [1] Group 1 - The board meeting is scheduled for March 23, 2026 [1] - The meeting will focus on approving the annual performance announcement for the fiscal year ending December 31, 2025 [1] - The company will also consider the distribution of a final dividend during this meeting [1]

Core Viewpoint - China COSCO Shipping Holdings Co., Ltd. (中远海控) will hold a board meeting on March 19, 2026, to consider and approve the announcement of the company's and its subsidiaries' annual performance for the year ending December 31, 2025, and to consider the payment of a final dividend, if any [1] Group 1 - The board meeting is scheduled for March 19, 2026 [1] - The meeting will focus on the annual performance announcement for the year ending December 31, 2025 [1] - The board will also consider the payment of a final dividend [1]

Group 1 - Citigroup has raised the target price for Mercedes-Benz from €58 to €60 [1]

Core Viewpoint - The exclusive global licensing agreement between China National Pharmaceutical Group (China Biologic) and Sanofi for the innovative drug Rovaxtinib marks a significant milestone in the recognition of Chinese pharmaceutical companies by multinational corporations (MNCs) [4][14]. Group 1: Transaction Overview - The agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize Rovaxtinib globally, with potential total payments reaching up to $1.53 billion [1]. - This transaction is notable as it is the first innovative drug licensing project between a Chinese pharmaceutical company and an MNC in recent years, highlighting the growing trust and collaboration in the industry [4][14]. Group 2: Product Significance - Rovaxtinib is the world's first JAK/ROCK dual-target small molecule inhibitor, demonstrating significant clinical value in treating myelofibrosis and chronic graft-versus-host disease (cGVHD) [8][10]. - The drug has shown promising clinical data, with a 59.1% improvement in graft-versus-host symptoms and an 86.4% overall response rate in clinical trials [13]. Group 3: Strategic Implications - For China Biologic, the transaction provides immediate financial benefits and long-term revenue stability through milestone payments and sales sharing [14]. - Sanofi can leverage its global resources to maximize Rovaxtinib's market potential, aligning with its existing pipeline in hematological diseases [14]. Group 4: Industry Trends - The deal signifies a shift in the industry, where the full-chain R&D capabilities of Chinese pharmaceutical companies are increasingly recognized by MNCs, enhancing mutual trust [4][15]. - China Biologic's successful collaboration with Sanofi reflects its robust innovation pipeline and growing international presence, paving the way for future global partnerships [15][17].

Group 1 - The core viewpoint of the article is that BYD has launched its second-generation blade battery and is expanding its fast-charging network, alongside introducing 10 new pure electric and plug-in hybrid models, with deliveries expected to start in April or May [1] - Morgan Stanley projects BYD's sales to rebound from approximately 700,000 units in Q1 to between 1.1 million and 1.2 million units in Q2 [1] - Investor focus is anticipated to shift towards the increase in foot traffic at stores around the Beijing Auto Show on April 24 [1] Group 2 - Morgan Stanley maintains a target price of HKD 110 for BYD and has rated the stock as "Overweight" [1]

Core Viewpoint - Bank of America Securities reports that JD Logistics exceeded expectations in Q4 of last year, driven by a decrease in operating expenses [1] Group 1: Financial Performance - Management is optimistic about the outlook for fiscal year 2026, guiding for revenue growth of 20% to 25% and non-IFRS net profit growth of 25% to 30% [1] - If these targets are met, it implies an upside potential of 15% to 20% on current profit forecasts, exceeding the most optimistic investor assumptions by approximately 10% to 15% [1] Group 2: Valuation and Rating - The projected price-to-earnings ratio for fiscal year 2026 is expected to be below 7 times [1] - The firm maintains a "Buy" rating on the stock with a target price of HKD 15 [1]

Group 1 - The core viewpoint of the article is that BYD has launched its second-generation blade battery and fast-charging technology, significantly improving charging times and performance compared to the first generation [1] - The second-generation blade battery can be charged in 5 to 9 minutes at normal temperatures, while the first generation required about 30 minutes [1] - In extremely cold weather, the charging time is less than 12 minutes, and the new battery maintains over 85% capacity at -20 degrees Celsius [1] Group 2 - The energy density of the second-generation blade battery has increased by 5% compared to the first generation, enabling a range of over 1000 kilometers [1] - Bank of America Securities has reiterated a "Buy" rating for BYD with a target price of HKD 122, citing increased contributions from overseas business as a factor that should help improve gross margins [1]